

**POLIO**

**GLOBAL  
ERADICATION  
INITIATIVE**

# Financial Resource Requirements 2010-2012

As of May 2010

**EVERY  
LAST  
CHILD**



**World Health  
Organization**

Partners in the Global Polio  
Eradication Initiative



© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

Photo: UNICEF/PAKA2008-0107/Shehzad Noorani (front cover) and Jersey Rotary/Richard Wainwright (back cover)

Design & Layout: [paprika-annecy.com](http://paprika-annecy.com)

# Table of Contents

1. Executive summary.....	2
2. Financial Resource Requirements 2010-2012 .....	5
3. Roles and Responsibilities of Spearheading Partners .....	6
4. Definition of the GPEI Activities and Budget Estimates .....	6
5. Polio Research .....	13
6. Review of the GPEI Budgets and Allocation of Funds .....	13
7. Post-eradication era .....	14
8. Donors .....	14
9. Annexes .....	16
10. Acronyms and abbreviations.....	23

# 1. Executive summary

Since the most recent Financial Resource Requirements document (FRR) was issued in February, the operational approaches laid out in the new *Global Polio Eradication Initiative (GPEI) Strategic Plan 2010-2012* are already bearing fruit.

Among the four endemic countries, wild poliovirus type 1 has not been detected for four months in northern Nigeria and the northern Indian states of Uttar Pradesh and Bihar. Two of the four countries with probable re-established transmission of an imported virus, the Democratic Republic of the Congo and Sudan, have not reported cases for over six months. Similarly, 10 of the 15 previously polio-free countries that were re-infected in 2009 had already stopped their outbreaks<sup>1</sup>.

The fragility of this progress – made all the more fragile by the substantial gap in financing – is drummed home by new importations of polio into Nepal, Senegal and Tajikistan (the last of which is in the WHO European Region, polio-free since 2002).

Since February, insufficient financing has forced the cancellation of planned activities in Burundi, Rwanda, Kenya, Uganda, Djibouti, Eritrea, Yemen and the Congo, the scaling back of planned activities in the Democratic Republic of the Congo and Ethiopia (see Annex A) and cuts to surveillance and campaign budgets in the WHO African Region.

Achieving the milestones outlined in the *Strategic Plan 2010-2012* will require – in addition to full ownership and engagement of the political leadership at all levels in the remaining polio-infected countries – the continued support of the international development community to rapidly make available the necessary financial resources.

This FRR outlines the range of activities and funding that will be required to finance the *Strategic Plan 2010-2012*, to successfully interrupt wild poliovirus transmission globally and prepare for the post-eradication era. Priorities will be reviewed quarterly, based on epidemiology and available financing.

For core running costs, all planned supplementary activities and emergency response, the budget is US\$ 2.6 billion and the funding gap is US\$ 1.3 billion. The FRR will be updated quarterly, based on the prevailing epidemiological and financial situation.

The four major targets of the new *GPEI Strategic Plan 2010-2012* are to stop wild poliovirus transmission:

- by mid-2010 in all countries with new outbreaks in 2009<sup>2</sup>;
- by end-2010 in the countries with re-established transmission<sup>3</sup>;
- by end-2011 in two of the four endemic countries<sup>4</sup>;
- by end-2012 in the remaining two endemic countries.

Progress against these targets will be independently analyzed every quarter and graded as 'on-track', 'progressing but with issues of concern' or 'at risk for completion' to alert countries and stakeholders as to emerging risks and guide mid-course corrections.

Failure to meet the financial requirements of eradication has human consequences, in terms of children paralyzed for life by a disease which is entirely vaccine-preventable, as well as the economic consequences of ongoing supplementary immunization in perpetuity in order to maintain the current number of cases. But most compelling are the ethical consequences: failing to protect future generations when the tools are available to do so.


<sup>1</sup> Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Côte d'Ivoire, Guinea, Kenya, Togo and Uganda.

<sup>2</sup> Validated when at least six months have passed without a polio case genetically linked to an importation event from 2009 (i.e. by Q4 2010)


<sup>3</sup> Validated when at least 12 months have passed without a polio case genetically linked to the re-established transmission train (i.e. by Q4 2011)

<sup>4</sup> Validated when at least 12 months have passed without a polio case genetically linked to an indigenous virus (i.e. by Q4 2012)

**Figure 1: Annual expenditure 1988-2009, FRR, Contributions and Funding Gap 2010-2012 (All figures in US\$ millions)**



**Figure 2: Financing 2010 to 2012: US\$ 1.3 billion contributions**



'Other' includes: the Governments of Finland, Portugal, Qatar, Turkey, UNICEF Regular and Other Resources.

Table 1: Summary of external resource requirements for global polio eradication by major category of activity, 2010-2012 (All figures in US\$ millions)

Core Cost	2010	2011	2012	2010-2012
Emergency response	\$45.00	\$35.00	\$25.00	\$105.00
Surveillance	\$56.79	\$63.75	\$65.65	\$186.19
Laboratory	\$7.90	\$8.46	\$8.69	\$25.04
Technical assistance	\$132.78	\$138.16	\$141.94	\$412.88
Social Mobilization Annual cost	\$21.69	\$18.83	\$15.32	\$55.84
Certification and containment	\$5.00	\$10.00	\$10.00	\$25.00
Product development for OPV cessation	\$16.54	\$5.00	\$5.00	\$26.54
Vaccine for post-eradication era stockpile (finished product and bulk)	\$12.30	-	\$36.92	\$49.22
<b>1<sup>st</sup> Priority Activities</b>				
Oral polio vaccine	\$272.74	\$180.94	\$176.78	\$630.46
NIDs/SNIDs operations*	\$252.24	\$141.90	\$132.32	\$526.46
Social Mobilization for SIA	\$25.50	\$25.43	\$20.14	\$71.07
<b>Subtotal</b>	<b>\$848.49</b>	<b>\$627.47</b>	<b>\$637.75</b>	<b>\$2 113.71</b>
<b>Contributions</b>	<b>\$658.55</b>	<b>\$312.87</b>	<b>\$295.33</b>	<b>\$1 266.75</b>
<b>Funding gap</b>	<b>\$189.94</b>	<b>\$314.60</b>	<b>\$342.42</b>	<b>\$846.96</b>
<b>Funding gap (rounded)</b>	<b>\$190.00</b>	<b>\$315.00</b>	<b>\$340.00</b>	<b>\$845.00</b>
<b>2<sup>nd</sup> Priority Activities</b>				
Oral polio vaccine	\$15.48	\$66.71	\$78.15	\$160.34
NIDs/SNIDs operations	\$22.24	\$65.03	\$76.15	\$163.42
Social Mobilization for SIA	\$0.20	\$1.68	\$3.75	\$5.62
<b>Subtotal</b>	<b>\$37.92</b>	<b>\$133.42</b>	<b>\$158.05</b>	<b>\$329.38</b>
<b>3<sup>rd</sup> Priority Activities</b>				
Oral polio vaccine	\$3.90	\$18.65	\$21.45	\$44.00
NIDs/SNIDs operations	\$1.58	\$35.32	\$37.67	\$74.57
Social Mobilization for SIA	\$0.46	\$2.07	\$2.04	\$4.56
<b>Subtotal</b>	<b>\$5.94</b>	<b>\$56.04</b>	<b>\$61.15</b>	<b>\$123.13</b>
<b>Grand Total (Core Cost &amp; 1<sup>st</sup>, 2<sup>nd</sup> &amp; 3<sup>rd</sup> Priority Activities)</b>	<b>\$892.35</b>	<b>\$816.93</b>	<b>\$856.95</b>	<b>\$2 566.23</b>
<b>Funding Gap (Core Cost &amp; 1<sup>st</sup>, 2<sup>nd</sup> &amp; 3<sup>rd</sup> Priority Activities)</b>	<b>\$233.80</b>	<b>\$504.06</b>	<b>\$561.62</b>	<b>\$1 299.48</b>

\* Operations costs include manpower and incentives, training and meetings, supplies and equipment, transportation, and running costs.

## 2. Financial Resource Requirements 2010-2012


This Financial Resource Requirements document (FRR) outlines the budget to implement the core strategies to stop polio and – in keeping with the country-driven *Strategic Plan 2010-2012* – to institutionalize recent innovations to improve the quality of intensified SIAs, increase technical assistance to countries with re-established polio transmission, enhance surveillance, systematize the synergies between immunization systems and polio eradication and expand pre-planned vaccination campaigns across the “importation belt” of sub-Saharan Africa. Filling sub-national surveillance gaps, revitalizing surveillance in polio-free regions and implementing new global surveillance strategies are also costed in the 2010-2012 budget.

The FRR is regularly updated based on evolving epidemiology; this is the second issue of the year<sup>5</sup>. SIAs have been prioritized according to epidemiology, the milestones in the *Strategic Plan* and the strategic objectives of strengthening immunization systems and ensuring sustainable surveillance for polioviruses.

If funding is insufficient to fund core costs and all supplementary activities, priority will be placed on covering core costs and implementing activities in areas of ongoing poliovirus transmission, followed by activities to reduce the risk of international spread.

Endemic countries account for 71% of the country budgets; countries with re-established transmission for 11%; re-infected countries and areas at high risk for 15%.

Figure 3: Comparison of Country Budgets for 2010\*



\*As a percentage of 1<sup>st</sup>-level priority country-level vaccine, operational and surveillance costs.

5 While the FRR provides overall budget estimates, detailed budgets are available upon request.

Recent studies on the cost-effectiveness of polio eradication demonstrate that where eradication is feasible, “control” is never the most cost-effective option. In contrast to the US\$ 2.6 billion budget presented here, an estimated US\$ 10 billion would be needed over a 20-year period to maintain polio cases at current levels, were the goal of eradication to be abandoned<sup>6</sup>. Just as high-cost “control” is not sustainable, low-cost “control” is not effective, since depending on routine immunization alone would lead to 200,000 to 250,000 cases per year. Neither is optimal when eradication is feasible.<sup>7</sup>

### 3. Roles and Responsibilities of Spearheading Partners

The spearheading partners of the GPEI are the World Health Organization (WHO), Rotary International, the United States Centers for Disease Control and Prevention (CDC) and the United Nations Children’s Fund (UNICEF). Rotary International is the leading private-sector donor to polio eradication, advocates with governments and communities and provides field-level support in SIA implementation and social mobilization. CDC deploys a wide range of public health assistance in the form of staff and consultants, provides specialized laboratory and diagnostic expertise and contributes funding.

The budgets that underpin the FRR are prepared by WHO, UNICEF and national governments.

The funds to finance polio eradication activities flow from multiple channels, primarily through these stakeholders. The national governments manage polio eradication activities; UNICEF usually takes the lead in procuring vaccine and conducting social mobilization activities and WHO provides technical assistance and supports surveillance. Both UN agencies support the government in the preparation and implementation of Supplementary Immunization Activities (SIAs).

### 4. Definition of the GPEI Activities and Budget Estimates

A robust system of estimating costs drives the development of the global budget estimates from the micro-level up. A schedule for SIAs is drawn up based on the guidance of national technical advisory groups (TAGs), Ministries of Health and the country offices of WHO and UNICEF. In 2009, for example, 2.2 billion doses of OPV were administered to more than 361 million children during 273 polio vaccination campaigns.<sup>8</sup>

The recommended schedule of SIAs is used by national governments, working with WHO and UNICEF, to develop budget estimates. These are based on plans drawn up for SIAs at the local level and take into consideration local costs for all elements of an activity – trainings, community meetings, posters, announcements, vaccinator payments, vehicles, fuel, supplies, etc.

<sup>6</sup> Thompson KM, Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. *Lancet*. 2007; 369(9570): 1363-71.

<sup>7</sup> Barrett S, Economics of eradication vs control of infectious diseases, , *Bulletin of the WHO*, Volume 82, Number 9, September 2004, 639-718.

<sup>8</sup> OPV was given during 102 National Immunization Days, 122 Sub-national Immunization Days, 28 mop-up campaigns and 21 Child Health Days). Children may have received more than one dose of OPV.



## 4.1. Cost Drivers of the GPEI Budget

The key cost drivers of the GPEI budget are oral polio vaccine (OPV) and SIA operations, followed by surveillance and technical assistance (See Table 1, Page 4).<sup>9</sup>


### 4.1.1. ORAL POLIO VACCINE

UNICEF is the agency that procures vaccine for the GPEI, and works to ensure OPV supply security (with multiple suppliers), at a price that is both affordable to governments and donors and reasonably covers the minimum needs of manufacturers.

For activities in areas with active poliovirus transmission, more than 1.5 billion doses of OPV will be required in 2010. The supply landscape has become more complex since 2005 with the introduction of two types of monovalent OPV (types 1 and 3) and, in 2010, bivalent OPV. This has contributed to a rise in the weighted average price of OPV from US\$ 0.08 per dose to approximately US\$ 0.14 per dose since 2000. The flexibility of manufacturers, to adjust production based on the OPV formulation required, comes at a cost. Currency fluctuations, the demand for high titres and the finite lifespan of OPV – for which demand will drop after the eradication of polio – also contribute to this price increase.

Despite these factors, the weighted average price of each OPV dose in 2009 (US\$ 0.137) and 2010 (US\$ 0.141) is lower than that in 2008 (US\$ 0.142).

Figure 4: OPV Supply & Weighted Average Price, 2000 to 2010



<sup>9</sup> For 2010, for example, OPV accounts for 35% of the budget, operations for 40%, technical assistance for 14% and surveillance for 8%, the remainder being dedicated to laboratories, research activities, etc.

### 4.1.2. OPERATIONS COSTS


SIA's are vast operations to deliver vaccine to every household: micro-plans have to be drawn up or updated for every dwelling in the area to be covered, whether a single district or an entire country. Vaccine has to be delivered to distribution centres throughout the target area. Vaccinators have to be trained to vaccinate children and mark fingers and houses, to document their work, to report their activities, to communicate with families appropriately, and so on. Vaccinators have to visit every household; supervisors and monitors have to scour every street for unvaccinated children.

Major factors affecting operations costs are the relative strength of the local infrastructure – whether it be roads, telecommunications or any of a host of facilities – and the local health system, the local economy, availability of semi-skilled workers, security conditions and population density. In 2009, 1.4 million paid vaccinators worked in SIA's; vaccinator per diems – to cover basic needs such as food and transport – constitute a large portion of operations costs.<sup>10</sup>

Additionally, communications support for immunization outreach must overcome limitations imposed through geography, literacy and local capacity to engage communities both through health workers and more traditional networks, and especially to target high risk groups who are typically underserved and have less access to health services.

Together, these factors contribute to the differences in operations costs, both between and within countries. In India, where operations costs are among the lowest in the endemic countries (cost per child US\$ 0.14 in 2010), high population density allows a single health or communication initiative to reach large swathes of the community. Chad, on the other hand, is one of the most expensive places in the world to conduct polio eradication operations (cost per child US\$ 0.63 in 2010), as interventions must reach a sparse and widely scattered population in a country with a very weak health infrastructure. While there is variability from one country to another as well as within countries, the average SIA operational costs per round per child has varied little from 2000 to the present (US\$ 0.24 per child to \$ 0.20 per child, inflation-adjusted).

Figure 5: Operations Cost Per Child, 2010\* (All figures in US\$)



\* Inflation-adjusted and excluding vaccine


10 Based on local rates for semi-skilled labour and government remuneration for similar tasks.

### 4.1.3. SURVEILLANCE

Surveillance budgets cover the detection and reporting of acute flaccid paralysis (AFP) cases, through both an extensive informant network of people who first report cases of AFP and active searches in health facilities for such cases. Subsequent case investigation is followed by collection of two stool samples, transportation to the appropriate laboratory, testing and genetic sequencing, the range of activities related to the management of the information and data generated. The Global Polio Laboratory Network comprises 145 facilities, which in 2009 tested over 150,000 stool samples (from nearly 90,000 cases of AFP and other sources).


Some of the other activities included under surveillance budget lines are the training of personnel to carry out each of the steps outlined above, as well as regular reviews of the surveillance systems and the purchase and maintenance of equipment, from photocopiers to vehicles. The average cost per AFP case reported dropped from a high of more than US\$ 1,500 in the year 2000, when there was heavy investment in establishing the infrastructure for AFP surveillance to approximately US\$ 700 per case since 2006. The range among countries in cost per AFP case investigated is based on factors similar to those which affect differences in SIA costs.

Figure 6: Surveillance Cost per AFP Case Analysis, 2009 (All figures in US\$)



To be updated for 2010 at the end of the year.

Figure 7: Average Cost Per AFP Case Reported in Endemic Regions (All figures in US\$)\*



#### 4.1.4. TECHNICAL ASSISTANCE


GPEI-funded technical assistance (staff and consultants) is deployed to fill capacity gaps when relevant skills are not available within a national health system, to build capacity and to facilitate international information exchange. The priorities for technical assistance are therefore driven by the relative strength of health systems in polio-affected countries as well as how critical the country is to global polio eradication. Matched against the number of children under the age of five years (i.e. the “target population”), technical assistance in countries with re-established transmission is on a par with – or even above – that in endemic countries (Figure 9).

In the 2010 budget, technical assistance is heavily weighted towards the polio-endemic countries (44% of cost), with the next concentration of funds in countries with re-established transmission (17% of cost) and re-infected countries and high-risk areas (12% of cost).<sup>11</sup>

This assistance provides the human resources necessary for immunization campaign planning, including communication and social mobilization strategy development and implementation, micro-planning, logistics, forecasting and supply management. Funding ensures resources are in place for overall communication capacity development, management skills in strategic planning, finance, human resources and social mobilization in a programme that manages some 20 million workers and volunteers, and communication efforts that help reach over 360 million children each year multiple times with OPV. Finally, technical assistance maintains the surveillance network, which provides reporting on AFP incidence from every district in the world on a weekly basis.

<sup>11</sup> The remaining 26% is allocated to polio-free regions, regional offices and eadquarters.

Figure 8: Technical Assistance by target population\*




\* as of March 2010

Table 2: WHO Technical Assistance by category of polio-infected country, 2010 (All figures in US\$)

Category	Total Cost	% of Cost	International	National
Endemic	\$51 170 000	44%	58	1 704
Countries with re-established transmission	\$19 911 000	17%	26	583
Countries with recurrent importations	\$11 134 000	10%	7	77
Other Importation-Affected Countries	\$2 680 000	2%	37	795
Outbreak response	\$0	0%		
Polio-Free	\$7 760 000	7%	7	0
Regional Offices	\$4 645 000	4%	23	23
HQ	\$17 730 250	15%	56	0
<b>GRAND TOTAL</b>	<b>\$115 030 250</b>		<b>214</b>	<b>3 182</b>

Figure 9: Geographic distribution of WHO technical assistance for polio eradication



Technical assistance on this scale is unique in public health and essential to finishing polio eradication. Polio eradication staff now constitute the single largest resource of technical assistance for immunization in low-income countries. For example, in 2009, of the 998 immunization staff in the WHO African Region, 940 (94%) were funded by the polio programme; at national or sub-national level, this proportion sometimes rose to 100%. In each component of a strong immunization system – logistics, service delivery, monitoring and supervision, surveillance and community participation – polio eradication staff have a wealth of experience.

Working to contribute to the objectives of the Global Immunization Vision and Strategy<sup>12</sup>, GPEI staff will designate a minimum of 25% of their time to specific 'high impact' tasks and activities to strengthen immunization systems. Capacity-building workshops on the intersections between immunization systems and polio eradication are also part of the *Strategic Plan 2010-2012*. Priority will be given to areas at highest risk of outbreaks following importations, especially those in sub-Saharan Africa.

<sup>12</sup> *Global Immunization Vision and Strategy 2006-2015*. World Health Organization / UNICEF, 2005.

## 5. Polio Research

In the GPEI *Strategic Plan 2010-2012*, the role of research continues to expand. The research agenda helps identify ways to reach more children and to enhance both humoral and mucosal immunity in targeted populations. *The Independent Evaluation of Major Barriers to Interrupting Poliovirus Transmission* endorsed the programmatic decision to intensify operational research. Scientific and operational research are guided by the Polio Research Committee, composed of experts in epidemiology, public health communications, virology and immunology.

Going forward, the research agenda encompasses expanded work in operational as well as scientific research. The former includes intervention studies to evaluate innovative approaches to further increase vaccination coverage and population immunity; to develop and evaluate tools to improve SIA and AFP surveillance management; and to evaluate vaccinator performance and assess ways to improve performance.

Among the studies being carried out or planned are those to improve understanding of both the evolving epidemiology of wild poliovirus and potential interventions to boost mucosal or “gut” immunity to address low vaccine efficacy in northern India, where the “threshold” to protect children is higher than anywhere else on earth.<sup>13</sup> Research will also focus on ways to lower that threshold, through add-ons such as zinc, as well as water and sanitation measures. Studies will be implemented to investigate the risk factors for decreased mucosal immunity; to evaluate possible interventions to boost mucosal immunity; and if possible, to assess potential surrogate measures of mucosal immunity against poliovirus.

## 6. Review of the GPEI Budgets and Allocation of Funds

The GPEI budget development is paired with a regular, interactive process of reviewing and reprioritizing activities in light of evolving epidemiology and available resources.

Twice a year, the Global Polio Management Team (GPMT) formally reviews the epidemiology of poliovirus globally and the SIA priorities based on principles established annually by the Advisory Committee on Poliomyelitis Eradication (ACPE) and reviewed by the Strategic Advisory Group of Experts on Immunization (SAGE). An in-depth weekly epidemiological review is complemented by weekly and bi-weekly teleconference check-ins between WHO and UNICEF headquarters and regional offices which provide opportunities to adjust allocations. The FRR is therefore updated regularly to adapt to the changing epidemiology and priorities.

After a budget review process at the regional office and headquarters levels, funds for country SIAs are released from WHO and UNICEF headquarters to regions and then countries. For staff and surveillance, funds are disbursed on a quarterly or semi-annual basis, depending on the GPEI cash flow. For most countries, funds for OPV are released by UNICEF six to eight weeks before SIAs.

Starting in the 4<sup>th</sup> quarter of 2010, a new global advisory body will evaluate the milestones and major process indicators, monitor corrective action plans and provide overall guidance on policy, strategy and priorities. This body will work closely with the SAGE, consulting on its findings at each of the six-monthly SAGE meetings.

<sup>13</sup> Population immunity levels must reach at least 95% to interrupt transmission of poliovirus in northern India, whereas levels of 75-80% have sufficed in Africa.

## 7. Post-eradication era

After interruption of wild poliovirus transmission and certification of that achievement, the budget of the GPEI will be driven primarily by the costs of maintaining AFP surveillance and laboratory capacity and outbreak response capacity for circulating vaccine-derived poliovirus. This capacity will be required until and during the cessation of routine OPV use globally and the subsequent verification of the elimination of vaccine-associated paralytic polio (VAPP) and vaccine-derived polioviruses (VDPV).

Consequently, annual financial resource requirements of the GPEI in the post-eradication period will be significantly lower than the (current) costs associated with the intensified polio eradication effort. The annual costs of these activities during the VAPP/VDPV Elimination Phase are estimated to be at least US\$150 million. The major uncertainty pertaining to GPEI costs during this period is the extent to which low- and low/middle-income countries will use IPV, how they will use it (e.g. fractional doses, reduced dose schedules) and how IPV will be produced at that time.

The costs of the GPEI will stop once VAPP/VDPV elimination is verified. All long-term functions will by that point have been incorporated into existing mechanisms for managing the residual risks associated with eradicated and/or dangerous pathogens (e.g. smallpox) and routine immunization programmes.

## 8. Donors

Since the 1988 World Health Assembly (WHA) resolution to eradicate polio, funding commitments have totalled US\$ 8.2 billion. In addition to contributions by national governments to their own polio eradication efforts, 45 public and private donors have each given more than US\$ 1 million, with 19 of these having given US\$ 25 million or more.

Donors to the GPEI include a wide range of donor governments, private foundations (e.g. Rotary International, BMGF, UN Foundation), multilateral organizations, development banks, NGOs and corporate partners. Several of these partners have contributed in excess of US\$250 million to the global eradication effort, including the United States of America, Rotary International, India, the United Kingdom, the World Bank, BMGF, Germany, Japan and Canada.

International contributions to national polio eradication efforts have been complemented by domestic resources. Of note, India has largely self-financed for the past several years, and in September 2009 re-affirmed its commitment by setting aside US\$ 657 million of its budget for polio eradication in the 2010-2012 period. Nigeria and Pakistan have also provided substantial domestic resources towards eradicating polio. Other contributions from polio-affected countries – including both financial and non-monetary expenditures, and in-kind contributions such as the time spent by volunteers, health workers and others in the planning and implementation of SIAs – are estimated to have a dollar value approximately equal to that of international financial contributions.<sup>14</sup>

<sup>14</sup> Aylward R, et al, Politics and practicalities of polio eradication, *Global Public Goods for Health. Health Economic and Public Health Perspectives*, editors Smith R, Beaglehole R, Woodward D, Drager N. Oxford University Press, 2003.




Table 3: Donor profile for 1985-2012

Contribution (US\$ million)	Public Sector Partners	Development Banks	Private Sector Partners
> 1.000	United State of America		Rotary International
500 - 1.000	United Kingdom	World Bank	Bill & Melinda Gates Foundation
250 - 499	Japan, Canada, Germany		
100 - 249	European Commission, Netherlands, GAVI/IFFIm, WHO Regular Budget		
50 - 99	Norway, UNICEF Regular Resources		
25 - 49	Denmark, France, Italy, Sweden, Russian Federation		United Nations Foundation
5 - 24	Australia, Ireland, Luxembourg, Spain		Sanofi Pasteur, IFPMA, UNICEF National Committees, American Red Cross, Oil for Food Program
1 - 4	Austria, Belgium, Finland, Kuwait, Malaysia, New Zealand, Portugal, Saudi Arabia, Switzerland, United Arab Emirates	Inter-American Development Bank, African Development Bank	Advantage Trust (HK), De Beers, International Federation of Red Cross and Red Crescent Societies, Pew Charitable Trust, Wyeth, Shinnyo-en, OPEC

Updated: 4 May 2010

Figure 10: Contributions and Pledges to the Global Polio Eradication Initiative, 1985-2012 (all figures in US\$ millions)





Annex B: Details of external funding requirements in polio-endemic and highest-risk countries, 2010-2012, as of 04 May 2010 (all figures in US\$ millions)

Country	2010					Total Costs
	AFP Surveillance	Social Mobilization	Technical Assistance	OPV	Op Costs	
<b>1. Endemic Countries</b>						
Afghanistan	\$2.51	\$2.02	\$3.97	\$9.14	\$13.98	\$31.62
India	\$8.26	\$14.00	\$16.02	\$134.73	\$86.09	\$259.10
Pakistan	\$2.43	\$7.96	\$7.39	\$41.85	\$23.46	\$83.09
*Nigeria	\$8.53	\$10.19	\$32.65	\$51.15	\$65.70	\$168.22
<b>2. Countries with re-established transmission</b>						
Chad	\$0.81	\$1.91	\$2.23	\$2.25	\$9.34	\$16.55
Sudan	\$2.37	\$2.08	\$5.83	\$5.64	\$12.65	\$28.57
Angola	\$1.46	\$2.28	\$5.39	\$3.52	\$5.74	\$18.39
Dem Rep of Congo	\$2.03	\$1.04	\$6.36	\$4.98	\$9.37	\$23.78
<b>3. Countries with recurrent importations</b>						
<b>West Africa</b>						
Niger	\$0.53	\$0.41	\$1.49	\$3.23	\$6.11	\$11.76
Benin	\$0.16	\$0.39	\$0.39	\$2.07	\$2.94	\$5.96
Burkina Faso	\$0.24	\$0.14	\$0.20	\$3.90	\$9.65	\$14.13
Côte d'Ivoire	\$0.26	\$0.49	\$1.29	\$3.30	\$3.20	\$8.54
Sierra Leone	\$0.20	\$0.34	\$0.71	\$1.16	\$2.32	\$4.74
Guinea	\$0.16	-	\$0.33	\$2.11	\$4.00	\$6.60
Liberia	\$0.20	\$0.11	\$0.44	\$0.51	\$1.52	\$2.77
Mali	\$0.23	\$0.23	\$0.40	\$3.03	\$6.26	\$10.14
Mauritania	\$0.16	\$0.20	\$0.06	\$0.66	\$2.24	\$3.33
Senegal	\$0.28	\$0.16	\$0.47	\$2.35	\$6.70	\$9.96
Guinea-Bissau	\$0.06	\$0.02	\$0.12	\$0.15	\$0.34	\$0.69
Gambia	\$0.05	\$0.10	\$0.05	\$0.18	\$0.44	\$0.82
Cape Verde	\$0.04	-	\$0.05	\$0.03	\$0.08	\$0.19
Togo	\$0.12	-	\$0.22	\$0.50	\$0.74	\$1.58
Ghana	\$0.33	\$0.27	\$0.10	\$1.86	\$2.17	\$4.74
<b>Horn of Africa</b>						
Ethiopia	\$2.76	\$0.74	\$2.83	\$0.94	\$1.44	\$8.70
*Somalia	\$0.76	\$0.42	\$2.60	\$1.50	\$1.37	\$6.65
Kenya	\$0.40	-	\$0.95	-	-	\$1.35
Uganda	\$0.36	\$0.92	\$0.58	-	-	\$1.86
Eritrea	\$0.12	\$0.02	\$0.11	-	-	\$0.25
Yemen	\$0.18	-	\$0.18	-	-	\$0.36
Djibouti	\$0.10	-	\$0.08	-	-	\$0.17
<b>Central Africa</b>						
Cameroon	\$0.37	\$0.25	\$0.59	\$0.74	\$0.86	\$2.81
Central African Republic	\$0.42	\$0.16	\$0.61	\$0.54	\$1.42	\$3.15
Congo	\$0.12	-	\$0.59	-	-	\$0.71
Burundi	\$0.08	-	\$0.04	-	-	\$0.12
Rwanda	\$0.10	\$0.28	\$0.63	-	-	\$1.01
<b>4. Other Importation-Affected Countries</b>						
<b>Southeast Asia</b>						
Bangladesh	\$0.90	-	\$1.42	\$7.88	\$2.01	\$12.21
Myanmar	\$0.52	-	\$0.43	\$2.22	\$0.70	\$3.87
Nepal	\$0.65	\$0.20	\$1.40	\$1.83	\$1.71	\$5.79
<b>Europe</b>						
Tajikistan	\$0.15	-	-	\$0.67	\$0.64	\$1.45
Uzbekistan	\$0.10	-	-	\$1.10	\$0.50	\$1.69
Kyrgyzstan	\$0.03	-	-	\$0.23	\$0.17	\$0.43

\* CHD/measles: Somalia & Nigeria only OPV is costed

## Annex B (continued)

Country	2011					Total Costs
	AFP Surveillance	Social Mobilization	Technical Assistance	OPV	Op Costs	
<b>1. Endemic Countries</b>						
Afghanistan	\$2.59	\$1.08	\$5.69	\$7.64	\$10.23	\$27.22
India	\$9.66	\$18.43	\$15.78	\$124.08	\$66.57	\$234.51
Pakistan	\$2.50	\$7.83	\$7.49	\$28.21	\$11.45	\$57.49
*Nigeria	\$9.89	\$8.11	\$34.99	\$34.93	\$48.10	\$136.01
<b>2. Countries with re-established transmission</b>						
Chad	\$0.72	\$1.81	\$2.95	\$2.24	\$6.11	\$13.82
Sudan	\$2.44	\$2.05	\$6.42	\$7.69	\$14.81	\$33.41
Angola	\$1.85	\$1.71	\$5.45	\$4.09	\$4.60	\$17.70
Dem Rep of Congo	\$2.58	\$1.06	\$6.57	\$8.99	\$16.67	\$35.86
<b>3. Countries with recurrent importations</b>						
<b>West Africa</b>						
Niger	\$0.68	\$0.40	\$1.53	\$3.48	\$5.82	\$11.90
Benin	\$0.21	\$0.40	\$0.83	\$2.24	\$3.30	\$6.97
Burkina Faso	\$0.35	\$0.57	\$0.27	\$3.75	\$7.45	\$12.40
Côte d'Ivoire	\$0.33	\$0.57	\$1.48	\$3.99	\$2.53	\$8.89
Sierra Leone	\$0.31	\$0.25	\$0.46	\$0.76	\$1.76	\$3.54
Guinea	\$0.15	-	\$0.35	\$1.50	\$3.79	\$5.80
Liberia	\$0.31	\$0.11	\$0.48	\$0.54	\$1.30	\$2.73
Mali	\$0.25	\$0.61	\$0.45	\$2.77	\$5.39	\$9.46
Mauritania	\$0.15	\$0.29	\$0.08	\$0.38	\$0.71	\$1.61
Senegal	\$0.29	-	\$0.76	\$0.90	\$2.34	\$4.30
Guinea-Bissau	\$0.07	\$0.11	\$0.13	\$0.11	\$0.21	\$0.64
Gambia	\$0.06	\$0.11	\$0.05	\$0.28	\$0.37	\$0.87
Cape Verde	\$0.05	-	\$0.10	\$0.05	\$0.06	\$0.27
Togo	\$0.15	\$0.07	\$0.40	\$0.63	\$0.61	\$1.86
Ghana	\$0.41	\$0.29	\$0.10	\$2.01	\$3.06	\$5.87
<b>Horn of Africa</b>						
Ethiopia	\$3.84	\$0.74	\$3.19	\$5.62	\$8.99	\$22.38
*Somalia	\$0.77	\$0.42	\$2.72	\$1.55	\$2.94	\$8.41
Kenya	\$0.50	-	\$0.97	\$1.01	\$1.89	\$4.39
Uganda	\$0.45	\$0.92	\$0.59	\$0.98	\$0.57	\$3.52
Eritrea	\$0.23	\$0.07	\$0.11	\$0.23	\$0.26	\$0.89
Yemen	\$0.18	-	\$0.19	\$0.95	\$3.08	\$4.40
Djibouti	\$0.10	-	\$0.16	\$0.03	\$0.29	\$0.58
<b>Central Africa</b>						
Cameroon	\$0.45	\$0.31	\$0.63	\$0.97	\$0.54	\$2.89
Central African Republic	\$0.54	\$0.20	\$0.63	\$0.56	\$1.25	\$3.17
Congo	\$0.15	-	\$0.61	\$0.28	\$0.57	\$1.62
Burundi	\$0.14	-	\$0.04	\$0.64	\$0.80	\$1.63
Rwanda	\$0.21	\$0.31	\$0.67	\$0.62	\$0.75	\$2.56
<b>4. Other Importation-Affected Countries</b>						
<b>Southeast Asia</b>						
Bangladesh	\$0.94	-	\$1.46	\$9.64	\$2.05	\$14.09
Myanmar	\$0.54	-	\$0.44	\$0.00	\$0.00	\$0.98
Nepal	\$0.63	\$0.21	\$1.46	\$1.96	\$1.12	\$5.37
<b>Europe</b>						
Tajikistan	\$0.15	-	-	-	-	\$0.15
Uzbekistan	\$0.10	-	-	-	-	\$0.10
Kyrgyzstan	\$0.03	-	-	-	-	\$0.03

\* CHD/measles: Somalia & Nigeria only OPV is costed

## Annex B (continued)

Country	2012					Total Costs
	AFP Surveillance	Social Mobilization	Technical Assistance	OPV	Op Costs	
<b>1. Endemic Countries</b>						
Afghanistan	\$2.66	\$1.08	\$5.84	\$6.41	\$8.17	\$24.17
India	\$8.76	\$15.60	\$16.25	\$127.81	\$65.40	\$233.82
Pakistan	\$2.58	\$7.81	\$7.69	\$29.93	\$12.02	\$60.03
*Nigeria	\$10.18	\$4.66	\$36.06	\$37.05	\$53.17	\$141.13
<b>2. Countries with re-established transmission</b>						
Chad	\$0.74	\$1.77	\$3.01	\$2.37	\$6.32	\$14.21
Sudan	\$2.51	\$1.67	\$6.62	\$8.16	\$15.45	\$34.41
Angola	\$1.91	\$1.89	\$5.60	\$4.34	\$4.41	\$18.14
Dem Rep of Congo	\$2.65	\$1.06	\$6.80	\$9.54	\$17.44	\$37.48
<b>3. Countries with recurrent importations</b>						
<b>West Africa</b>						
Niger	\$0.70	\$0.40	\$1.58	\$3.69	\$6.02	\$12.39
Benin	\$0.21	\$0.42	\$0.61	\$2.38	\$3.40	\$7.01
Burkina Faso	\$0.36	\$0.57	\$0.28	\$3.98	\$7.69	\$12.88
Côte d'Ivoire	\$0.34	\$0.61	\$1.51	\$4.23	\$2.57	\$9.26
Sierra Leone	\$0.32	\$0.24	\$0.48	\$0.81	\$1.82	\$3.67
Guinea	\$0.16	-	\$0.41	\$1.59	\$3.90	\$6.06
Liberia	\$0.32	\$0.11	\$0.50	\$0.40	\$1.33	\$2.65
Mali	\$0.25	\$0.60	\$0.46	\$0.57	\$5.50	\$7.39
Mauritania	\$0.16	\$0.29	\$0.08	\$2.94	\$0.73	\$4.19
Senegal	\$0.30	-	\$0.77	\$0.81	\$2.41	\$4.29
Guinea-Bissau	\$0.07	\$0.13	\$0.14	\$2.13	\$0.20	\$2.67
Gambia	\$0.06	\$0.10	\$0.05	\$0.67	\$0.37	\$1.26
Cape Verde	\$0.05	-	\$0.11	\$0.93	\$0.07	\$1.16
Togo	\$0.16	\$0.07	\$0.42	\$0.11	\$0.62	\$1.38
Ghana	\$0.42	\$0.30	\$0.11	\$0.29	\$3.10	\$4.22
<b>Horn of Africa</b>						
Ethiopia	\$3.96	\$0.49	\$3.27	\$5.96	\$9.33	\$23.01
*Somalia	\$0.80	\$0.42	\$2.84	\$1.65	\$3.03	\$8.74
Kenya	\$0.52	-	\$1.00	\$1.07	\$1.95	\$4.55
Uganda	\$0.47	-	\$0.43	\$1.04	\$1.03	\$2.97
Eritrea	\$0.23	\$0.07	\$0.12	\$0.24	\$0.25	\$0.91
Yemen	\$0.18	-	\$0.19	\$1.01	\$3.00	\$4.39
Djibouti	\$0.10	-	\$0.17	\$0.03	\$0.30	\$0.60
<b>Central Africa</b>						
Cameroon	\$0.47	\$0.37	\$0.66	\$1.03	\$0.50	\$3.03
Central African Republic	\$0.55	\$0.20	\$0.65	\$0.59	\$1.33	\$3.32
Congo	\$0.16	-	\$0.63	\$0.30	\$0.58	\$1.67
Burundi	\$0.15	-	\$0.04	-	-	\$0.19
Rwanda	\$0.21	\$0.34	\$0.72	-	-	\$1.27
<b>4. Other Importation-Affected Countries</b>						
<b>Southeast Asia</b>						
Bangladesh	\$0.97	-	\$1.51	\$10.23	\$2.11	\$14.81
Myanmar	\$0.55	-	\$0.46	\$0.00	\$0.00	\$1.01
Nepal	\$0.65	\$0.22	\$1.52	\$2.08	\$1.14	\$5.61
<b>Europe</b>						
Tajikistan	\$0.15	-	-	-	-	\$0.15
Uzbekistan	\$0.10	-	-	-	-	\$0.10
Kyrgyzstan	\$0.03	-	-	-	-	\$0.03

\* CHD/measles: Somalia & Nigeria only OPV is costed

## Annex B (continued)

Country	2010 - 2012					Total Costs 2010-2012
	Total AFP Surveillance	Total Social Mobilization	Total Technical Assistance	Total OPV	Total Op Costs	
<b>1. Endemic Countries</b>						
Afghanistan	\$5.17	\$4.18	\$15.50	\$23.19	\$32.38	\$83.01
India	\$17.02	\$48.03	\$48.05	\$386.62	\$218.06	\$727.43
Pakistan	\$5.01	\$23.60	\$22.58	\$99.99	\$46.93	\$200.61
*Nigeria	\$18.72	\$22.96	\$103.69	\$123.13	\$166.97	\$445.35
<b>2. Countries with re-established transmission</b>						
Chad	\$1.56	\$5.49	\$8.19	\$6.86	\$21.77	\$44.58
Sudan	\$4.88	\$5.80	\$18.87	\$21.49	\$42.91	\$96.39
Angola	\$3.37	\$5.88	\$16.43	\$11.95	\$14.75	\$54.23
Dem Rep of Congo	\$4.68	\$3.15	\$19.73	\$23.50	\$43.48	\$97.12
<b>3. Countries with recurrent importations</b>						
<b>West Africa</b>						
Niger	\$1.23	\$1.20	\$4.61	\$10.40	\$17.94	\$36.05
Benin	\$0.37	\$1.21	\$1.82	\$6.68	\$9.64	\$19.93
Burkina Faso	\$0.60	\$1.28	\$0.75	\$11.62	\$24.79	\$39.40
Côte d'Ivoire	\$0.60	\$1.67	\$4.28	\$11.52	\$8.30	\$26.70
Sierra Leone	\$0.52	\$0.83	\$1.65	\$2.73	\$5.91	\$11.95
Guinea	\$0.32	-	\$1.09	\$5.20	\$11.69	\$18.46
Liberia	\$0.52	\$0.32	\$1.42	\$1.45	\$4.15	\$8.16
Mali	\$0.48	\$1.43	\$1.32	\$6.37	\$17.15	\$26.99
Mauritania	\$0.32	\$0.78	\$0.23	\$3.98	\$3.67	\$9.13
Senegal	\$0.58	\$0.16	\$2.01	\$4.06	\$11.45	\$18.54
Guinea-Bissau	\$0.13	\$0.26	\$0.39	\$2.39	\$0.75	\$4.00
Gambia	\$0.11	\$0.30	\$0.15	\$1.14	\$1.18	\$2.95
Cape Verde	\$0.09	-	\$0.26	\$1.00	\$0.21	\$1.62
Togo	\$0.28	\$0.14	\$1.04	\$1.24	\$1.97	\$4.82
Ghana	\$0.75	\$0.86	\$0.31	\$4.16	\$8.33	\$14.83
<b>Horn of Africa</b>						
Ethiopia	\$6.72	\$1.96	\$9.29	\$12.52	\$19.76	\$54.09
*Somalia	\$1.56	\$1.26	\$8.16	\$4.70	\$7.34	\$23.79
Kenya	\$0.92	-	\$2.93	\$2.09	\$3.84	\$10.28
Uganda	\$0.83	\$1.85	\$1.61	\$2.02	\$1.60	\$8.35
Eritrea	\$0.35	\$0.15	\$0.34	\$0.47	\$0.51	\$2.05
Yemen	\$0.36	-	\$0.56	\$1.97	\$6.08	\$9.15
Djibouti	\$0.20	-	\$0.41	\$0.05	\$0.59	\$1.35
<b>Central Africa</b>						
Cameroon	\$0.84	\$0.93	\$1.88	\$2.74	\$1.90	\$8.73
Central African Republic	\$0.97	\$0.56	\$1.89	\$1.68	\$4.00	\$9.63
Congo	\$0.28	-	\$1.83	\$0.58	\$1.15	\$4.00
Burundi	\$0.23	-	\$0.12	\$0.64	\$0.80	\$1.94
Rwanda	\$0.31	\$0.93	\$2.02	\$0.62	\$0.75	\$4.84
<b>4. Other Importation-Affected Countries</b>						
<b>Southeast Asia</b>						
Bangladesh	\$1.87	-	\$4.39	\$27.75	\$6.16	\$41.10
Myanmar	\$1.07	-	\$1.33	\$2.22	\$0.70	\$5.86
Nepal	\$1.30	\$0.62	\$4.38	\$5.87	\$3.97	\$16.77
<b>Europe</b>						
Tajikistan	\$0.30	-	-	\$0.67	\$0.64	\$1.76
Uzbekistan	\$0.20	-	-	\$1.10	\$0.50	\$1.89
Kyrgyzstan	\$0.05	-	-	\$0.23	\$0.17	\$0.48

\* CHD/measles: Somalia & Nigeria only OPV is costed

## ANNEX C: Surveillance and laboratory costs by country and region, 2010 (all figures in US\$ millions)

<b>WHO African Region</b>	<b>2010</b>	<b>WHO Region of the Americas</b>	<b>2010</b>
Algeria	\$0.05	Regional surveillance and laboratory	\$0.60
Angola	\$1.46		
Benin	\$0.16	<b>WHO Eastern Mediterranean Region</b>	<b>2010</b>
Botswana	\$0.08	Afghanistan	\$2.51
Burkina Faso	\$0.24	Djibouti	\$0.00
Burundi	\$0.08	Egypt	\$0.37
Cameroon	\$0.37	Iraq	\$0.10
Cape Verde	\$0.04	Pakistan	\$2.43
Central African Republic	\$0.42	Somalia	\$0.75
Chad	\$0.81	Sudan	\$2.37
Comoros	\$0.04	Yemen	\$0.18
Congo	\$0.12	Regional surveillance and laboratory	\$1.10
Côte d'Ivoire	\$0.26	<b>Subtotal</b>	<b>\$9.82</b>
Democratic Republic of Congo	\$2.03		
Equatorial Guinea	\$0.04	<b>WHO South-East Asia Region</b>	<b>2010</b>
Eritrea	\$0.12	Bangladesh	\$0.90
Ethiopia	\$2.76	India	\$8.26
Gabon	\$0.08	Indonesia	\$1.08
Gambia	\$0.05	Myanmar	\$0.52
Ghana	\$0.33	Nepal	\$0.65
Guinea	\$0.16	Regional surveillance and laboratory	\$3.49
Guinea-Bissau	\$0.06	<b>Subtotal</b>	<b>\$14.90</b>
Kenya	\$0.40		
Lesotho	\$0.04	<b>WHO European Region</b>	<b>2010</b>
Liberia	\$0.20	Tajikistan	\$0.15
Madagascar	\$0.33	Uzbekistan	\$0.10
Malawi	\$0.16	Kyrgyzstan	\$0.03
Mali	\$0.23	Regional surveillance and laboratory	\$1.06
Mauritania	\$0.16	<b>Subtotal</b>	<b>\$1.33</b>
Mauritius	\$0.02		
Mozambique	\$0.24	<b>WHO Western Pacific Region</b>	<b>2010</b>
Namibia	\$0.12	Regional surveillance and laboratory	\$1.23
Niger	\$0.53		
Nigeria	\$8.53	<b>WHO/HQ</b>	<b>2010</b>
Rwanda	\$0.10	WHO/HQ	\$9.41
Sao Tome and Principe	\$0.01		
Senegal	\$0.28	<b>Global</b>	<b>2010</b>
Seychelles	\$0.01	<b>Total</b>	<b>\$64.69</b>
Sierra Leone	\$0.20		
South Africa	\$0.24		
Swaziland	\$0.07		
Togo	\$0.12		
Uganda	\$0.36		
United Republic of Tanzania	\$0.37		
Zambia	\$0.33		
Zimbabwe	\$0.22		
Regional surveillance and laboratory	\$4.37		
<b>Subtotal</b>	<b>\$27.41</b>		

ANNEX D: Technical assistance, country-level details, 2010  
 (all figures in US\$ millions)

WHO African Region	2010
Angola	\$4.77
Benin	\$0.39
Botswana	\$0.23
Burkina Faso	\$0.20
Burundi	\$0.04
Cameroon	\$0.50
Central African Republic	\$0.61
Chad	\$1.73
Congo	\$0.45
Côte d'Ivoire	\$1.19
Democratic Republic of Congo	\$5.05
Equatorial Guinea	\$0.14
Eritrea	\$0.11
Ethiopia	\$2.55
Gabon	\$0.37
Gambia	\$0.05
Ghana	\$0.10
Guinea	\$0.10
Guinea-Bissau	\$0.12
Kenya	\$0.83
Lesotho	\$0.07
Liberia	\$0.44
Madagascar	\$0.25
Malawi	\$0.07
Mali	\$0.39
Mauritania	\$0.06
Mozambique	\$0.27
Namibia	\$0.13
Niger	\$1.49
Nigeria	\$26.87
Rwanda	\$0.31
Senegal	\$0.16
Sierra Leone	\$0.40
South Africa	\$0.31
Swaziland	\$0.09
Togo	\$0.19
Uganda	\$0.41
United Republic of Tanzania	\$0.34
Zambia	\$0.57
Zimbabwe	\$0.12
IST (Central block)	\$1.46
IST (South/East block)	\$1.24
IST (West block)	\$1.01
Regional Office	\$1.48
<b>Subtotal</b>	<b>\$57.81</b>
WHO European Region	2010
Regional Office/Countries	\$0.50
<b>Subtotal</b>	<b>\$0.50</b>
WHO/HQ	\$10.23
Short Term Tech Assistance	\$7.50
Global WHO-Unicef	2010
<b>Total</b>	<b>\$132.78</b>

\* IST= Inter-country Support Team

WHO Eastern Mediterranean Region	2010
Afghanistan	\$3.58
Djibouti	\$0.00
Egypt	\$0.03
Iran	\$0.01
Iraq	\$0.00
Pakistan	\$6.53
Somalia	\$2.00
Sudan	\$5.34
Yemen	\$0.18
Regional Office	\$1.17
<b>Subtotal</b>	<b>\$18.85</b>
WHO South-East Asia Region	2010
Bangladesh	\$1.42
India	\$14.18
Indonesia	\$0.88
Myanmar	\$0.43
Nepal	\$0.84
Regional Office	\$0.77
<b>Subtotal</b>	<b>\$18.52</b>
WHO Western Pacific Region	2010
Cambodia	\$0.10
China	\$0.30
Fiji	\$0.10
Lao PDR	\$0.10
Philippines	\$0.10
Papua New Guinea	\$0.10
Viet Nam	\$0.10
Regional Office	\$0.70
<b>Subtotal</b>	<b>\$1.61</b>
UNICEF	2010
Unicef/HQ	\$2.50
Afghanistan	\$0.38
Angola	\$0.62
Cameroon	\$0.09
Cape Verde	\$0.05
Chad	\$0.50
Congo	\$0.14
Côte d'Ivoire	\$0.10
Dem Rep of Congo	\$1.31
Djibouti	\$0.08
Ethiopia	\$0.28
Guinea	\$0.23
India	\$1.84
Kenya	\$0.12
Mali	\$0.01
Nepal	\$0.56
Nigeria	\$5.78
Pakistan	\$0.86
Rwanda	\$0.32
Senegal	\$0.31
Sierra Leone	\$0.31
Somalia	\$0.60
Sudan	\$0.49
Togo	\$0.03
Uganda	\$0.17
<b>Subtotal</b>	<b>\$17.76</b>



## 10. Acronyms and abbreviations

AFP	Acute flaccid paralysis
bOPV	Bivalent oral polio vaccine
CDC	US Centers for Disease Control and Prevention
GPEI	Global Polio Eradication Initiative
mOPV	Monovalent oral polio vaccine
NIDs	National Immunization Days
OPV	Oral polio vaccine
SIAs	Supplementary Immunization Activities
SNIDs	Sub-national Immunization Days
tOPV	Trivalent oral polio vaccine
UNICEF	United Nations Children's Fund
VAPP	Vaccine-associated paralytic polio
VDPV	Vaccine-derived poliovirus
WHO	World Health Organization
WPV	Wild poliovirus



[www.polioeradication.org](http://www.polioeradication.org)

EVERY  
LAST CHILD

